WO2025229584 - THE OREXIN RECEPTOR 2 (OX2R) AGONIST OVEPOREXTON/TAK-861 FOR USE IN NARCOLEPSY TYPE 1 (NT1)
National phase entry is expected:
Publication Number
WO/2025/229584
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054557
International Filing Date
30.04.2025
Title **
[English]
THE OREXIN RECEPTOR 2 (OX2R) AGONIST OVEPOREXTON/TAK-861 FOR USE IN NARCOLEPSY TYPE 1 (NT1)
[French]
AGONISTE DU RÉCEPTEUR 2 DE L'OREXINE (OX2R) DESTINÉ À ÊTRE UTILISÉ DANS LA NARCOLEPSIE DE TYPE 1 (NT1)
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
ABRAHAM, Anson
FAESSEL, Helene
HANG, Yaming
HAREL, Brian
KARAS, Marta
KIMURA, Haruhide
KOUNDOURAKIS, Elena
OLSSON, Tina
VON HEHN, Christian
VON ROSENSTIEL, Sebastian Philipp
SINHA, Vikram
VOLFSON, Dmitri
WANG, Hao
ZHU, Andy
Inventors
ABRAHAM, Anson
FAESSEL, Helene
HANG, Yaming
HAREL, Brian
KARAS, Marta
KIMURA, Haruhide
KOUNDOURAKIS, Elena
OLSSON, Tina
VON HEHN, Christian
VON ROSENSTIEL, Sebastian Philipp
SINHA, Vikram
VOLFSON, Dmitri
WANG, Hao
ZHU, Andy
Priority Data
63/641,320
01.05.2024
US
63/653,638
30.05.2024
US
63/675,599
25.07.2024
US
63/690,651
04.09.2024
US
63/697,871
23.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4179 | |
| EPO | Filing, Examination, Granting | 33057 | |
| Japan | Filing, Examination, Granting | 3350 | |
| South Korea | Filing, Examination, Granting | 4526 | |
| USA | Filing, Examination, Granting | 18390 |
Total:
63,502
Contact Us
Abstract[English]
Disclosed herein are methods, uses and composition for treating narcolepsy with cataplexy (narcolepsy type 1 or NT1), blunted nocturnal blood pressure dip in a subject having narcolepsy type 1 or cognitive impairment in a subject having narcolepsy type 1, by administering an orexin receptor 2 agonist to the subject at one or more daily dosages.[French]
L'invention concerne des méthodes, des utilisations et une composition pour traiter la narcolepsie avec cataplexie (narcolepsie de type 1 ou NT1), une diminution émoussée de la pression artérielle nocturne chez un sujet ayant une narcolepsie de type 1 ou une déficience cognitive chez un sujet ayant une narcolepsie de type 1, par administration d'un agoniste du récepteur 2 de l'orexine au sujet selon un ou plusieurs dosages quotidiens.